Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Medical Research

Neither a doctor nor a teaching hospital

Research payments

$6,109,734

2,680 payments

Through program year 2025, Advanced Medical Research is reported as receiving $6,109,734 in research payments, across 2,680 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $519,179 34
2024 Research $740,702 136
2023 Research $951,682 298
2022 Research $834,513 855
2021 Research $1,169,746 696
2020 Research $1,046,282 440
2019 Research $847,630 221

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ucb SA $1,544,322 68 payments
  2. Novo Nordisk AS $1,212,137 2,162 payments
  3. Merck Sharp & Dohme Corporation $809,000 26 payments
  4. Sanofi US Services Inc. $650,722 52 payments
  5. AbbVie, Inc. $583,939 154 payments
  6. Novartis Pharmaceuticals Corporation $398,366 18 payments
  7. AstraZeneca Pharmaceuticals LP $362,796 24 payments
  8. Genentech, Inc. $168,995 42 payments
  9. Eli Lilly and Company $137,558 3 payments
  10. Pfizer Inc. $86,515 19 payments
Studies the money was for Research payments · program years 2019–2025
  1. Ex9924-4473 $483,039 874 payments
  2. Ex9536-4388 $362,771 394 payments
  3. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $300,571 5 payments
  4. A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa $295,297 11 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $293,186 23 payments
  6. A Multicenter, Double-Blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-Term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa $281,363 6 payments
  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $262,045 8 payments
  8. A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older $254,261 5 payments
  9. A Phase 1,Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults $242,193 3 payments
  10. A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr $199,784 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record